Publication

Regulators of B-cell activity in SLE: a better target for treatment than B-cell depletion?

Dolff, S., Abdulahad, W. H., Bijl, M. & Kallenberg, C. G. M., Jun-2009, In : Lupus. 18, 7, p. 575-580 6 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

Dolff, S., Abdulahad, W. H., Bijl, M., & Kallenberg, C. G. M. (2009). Regulators of B-cell activity in SLE: a better target for treatment than B-cell depletion? Lupus, 18(7), 575-580. https://doi.org/10.1177/0961203309102296

Author

Dolff, S. ; Abdulahad, W. H. ; Bijl, M. ; Kallenberg, C. G. M. / Regulators of B-cell activity in SLE : a better target for treatment than B-cell depletion?. In: Lupus. 2009 ; Vol. 18, No. 7. pp. 575-580.

Harvard

Dolff, S, Abdulahad, WH, Bijl, M & Kallenberg, CGM 2009, 'Regulators of B-cell activity in SLE: a better target for treatment than B-cell depletion?', Lupus, vol. 18, no. 7, pp. 575-580. https://doi.org/10.1177/0961203309102296

Standard

Regulators of B-cell activity in SLE : a better target for treatment than B-cell depletion? / Dolff, S.; Abdulahad, W. H.; Bijl, M.; Kallenberg, C. G. M.

In: Lupus, Vol. 18, No. 7, 06.2009, p. 575-580.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

Dolff S, Abdulahad WH, Bijl M, Kallenberg CGM. Regulators of B-cell activity in SLE: a better target for treatment than B-cell depletion? Lupus. 2009 Jun;18(7):575-580. https://doi.org/10.1177/0961203309102296


BibTeX

@article{0c1d175ab5d4440eab6acfc7d40cf235,
title = "Regulators of B-cell activity in SLE: a better target for treatment than B-cell depletion?",
abstract = "B cells, being a source of characteristic antinuclear autoantibodies, play a crucial role in the pathogenesis of systemic lupus erythematosus (SLE). Evidences indicate that alterations in B-cell regulation are responsible for B-cell hyperactivity as seen in SLE. T cells, soluble factors, and even B cells themselves regulate effector B-cell functions. The latter, so-called regulatory B cells possess regulatory function through production of the cytokine interleukin-10 (IL-10) that can damp down the humoral immune responses. This review will focus on B-cell regulation in the pathogenesis of SLE as a target for intervention. In particular, the regulatory impact of T cells through costimulation, soluble factors such as B lymphocyte stimulator, and the characteristics of IL 10-producing regulatory B cells will be discussed. Therapies targeting B cells as well as B-cell regulation seem promising, but the precise mechanisms involved in these interventions are not completely understood. More insight into B-cell regulation in SLE, and particularly in regulatory B cells, could lead to novel therapeutic strategies.",
keywords = "B-cell regulation, SLE, IL-10, SYSTEMIC-LUPUS-ERYTHEMATOSUS, ANTI-DNA ANTIBODIES, LYMPHOCYTE STIMULATOR, RHEUMATOID-ARTHRITIS, AUTOIMMUNE-DISEASE, MONOCLONAL-ANTIBODY, CUTTING EDGE, MURINE LUPUS, T-CELLS, RITUXIMAB",
author = "S. Dolff and Abdulahad, {W. H.} and M. Bijl and Kallenberg, {C. G. M.}",
note = "Review",
year = "2009",
month = "6",
doi = "10.1177/0961203309102296",
language = "English",
volume = "18",
pages = "575--580",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Inc.",
number = "7",

}

RIS

TY - JOUR

T1 - Regulators of B-cell activity in SLE

T2 - a better target for treatment than B-cell depletion?

AU - Dolff, S.

AU - Abdulahad, W. H.

AU - Bijl, M.

AU - Kallenberg, C. G. M.

N1 - Review

PY - 2009/6

Y1 - 2009/6

N2 - B cells, being a source of characteristic antinuclear autoantibodies, play a crucial role in the pathogenesis of systemic lupus erythematosus (SLE). Evidences indicate that alterations in B-cell regulation are responsible for B-cell hyperactivity as seen in SLE. T cells, soluble factors, and even B cells themselves regulate effector B-cell functions. The latter, so-called regulatory B cells possess regulatory function through production of the cytokine interleukin-10 (IL-10) that can damp down the humoral immune responses. This review will focus on B-cell regulation in the pathogenesis of SLE as a target for intervention. In particular, the regulatory impact of T cells through costimulation, soluble factors such as B lymphocyte stimulator, and the characteristics of IL 10-producing regulatory B cells will be discussed. Therapies targeting B cells as well as B-cell regulation seem promising, but the precise mechanisms involved in these interventions are not completely understood. More insight into B-cell regulation in SLE, and particularly in regulatory B cells, could lead to novel therapeutic strategies.

AB - B cells, being a source of characteristic antinuclear autoantibodies, play a crucial role in the pathogenesis of systemic lupus erythematosus (SLE). Evidences indicate that alterations in B-cell regulation are responsible for B-cell hyperactivity as seen in SLE. T cells, soluble factors, and even B cells themselves regulate effector B-cell functions. The latter, so-called regulatory B cells possess regulatory function through production of the cytokine interleukin-10 (IL-10) that can damp down the humoral immune responses. This review will focus on B-cell regulation in the pathogenesis of SLE as a target for intervention. In particular, the regulatory impact of T cells through costimulation, soluble factors such as B lymphocyte stimulator, and the characteristics of IL 10-producing regulatory B cells will be discussed. Therapies targeting B cells as well as B-cell regulation seem promising, but the precise mechanisms involved in these interventions are not completely understood. More insight into B-cell regulation in SLE, and particularly in regulatory B cells, could lead to novel therapeutic strategies.

KW - B-cell regulation

KW - SLE

KW - IL-10

KW - SYSTEMIC-LUPUS-ERYTHEMATOSUS

KW - ANTI-DNA ANTIBODIES

KW - LYMPHOCYTE STIMULATOR

KW - RHEUMATOID-ARTHRITIS

KW - AUTOIMMUNE-DISEASE

KW - MONOCLONAL-ANTIBODY

KW - CUTTING EDGE

KW - MURINE LUPUS

KW - T-CELLS

KW - RITUXIMAB

U2 - 10.1177/0961203309102296

DO - 10.1177/0961203309102296

M3 - Review article

VL - 18

SP - 575

EP - 580

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 7

ER -

ID: 2004891